Case Summary:     

We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval granted to a medicinal chemistry researcher from abroad whose work is helping advance the discovery of bioactive small molecules for antimicrobial drug development. At the time of filing, the client was working in research with a Ph.D. in medicinal chemistry and had already built a record of notable contributions to drug discovery and medical applications.

Research Focus and Contributions:
 The client’s proposed endeavor is centered on designing and developing novel antimicrobial compounds to support in vitro and in vivo applications that directly contribute to treating a range of human diseases. His work is highly regarded for addressing urgent challenges in global health by creating new therapeutic options to combat resistant pathogens. The petition emphasized his expertise in integrating medicinal chemistry with applied biomedical research, bridging the gap between basic discovery and clinical translation.

Research Impact and Achievements:
 To highlight the client’s scientific influence, the petition presented multiple achievements:

• Publications: 25 peer-reviewed journal articles, including 8 as first author and 4 as corresponding author, along with 6 conference abstracts, demonstrating a strong and sustained research output.
• Citations: His publications have been cited 252 times in Google Scholar, reflecting their recognition and use by peers in medicinal chemistry and drug development.
• Peer Review: He has completed at least 110 reviews for respected journals, confirming his standing as a trusted authority in his field.
• Funding Evidence: The client’s research has been supported by major funding organizations, including CDMRP, NIH, and NSFC, underscoring the value and impact of his contributions.

Support from Experts in the Field:
 The petition was further strengthened by two recommendation letters from both affiliated and independent experts. These letters emphasized the importance of his work in advancing drug discovery and recognized his role as a leader in antimicrobial research.

“It is therefore within the interests of the United States to allow [Client’s] research to continue, benefiting public health and alleviating societal and economic burdens.”

Well Positioned to Advance the Proposed Endeavor:
 NAILG demonstrated that the client’s academic training, combined with a record of innovative publications, extensive peer-review service, and strong funding support, has uniquely positioned him to carry forward research that addresses urgent public health needs. His background equips him to continue advancing antimicrobial drug discovery with direct relevance to national and global health priorities.

NIW Approval and Outlook:
 Approved in March 2025, the petition was granted in recognition of the client’s demonstrated record of impactful contributions and his strong potential to continue making advances in drug discovery and development. NAILG is proud to have successfully represented this client and looks forward to seeing his ongoing work in medicinal chemistry strengthen the field of therapeutics and public health.